Jamo Hoekman1, Hiddo J Lambers Heerspink, Giancarlo Viberti, Damien Green, Johannes F E Mann, Dick de Zeeuw. 1. Department of Clinical Pharmacology, University of Groningen, University Medical Center, Groningen, The Netherlands;, †King's College London School of Medicine, Guy's Hospital, London, United Kingdom;, ‡Quintiles Ltd., Strasbourg, France;, §Schwabing General Hospital, Munich, Germany;, ‖Department of Medicine IV, University of Erlangen, Erlangen, Germany, ¶KfH Kidney Centre, Munich, Germany.
Abstract
BACKGROUND AND OBJECTIVES: The Avosentan on Time to Doubling of Serum Creatinine, End Stage Renal Disease or Death (ASCEND) trial tested the renoprotective effect of the endothelin receptor antagonist avosentan in patients with diabetes and nephropathy, but the study was terminated due to an excess of congestive heart failure (CHF) events in the avosentan arms, likely due to fluid retention. The aim of this study was to identify risk markers of CHF after treatment with avosentan. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a post hoc analysis of the ASCEND trial (N=1392 participants), we assessed which baseline characteristics predicted CHF risk during avosentan treatment. Furthermore, postrandomization changes between baseline and the first available measurement of body weight and hemoglobin were examined as potential clinical indicators of fluid retention for their relationship with CHF development. RESULTS: Relative to placebo, avosentan increased CHF risk (hazard ratio, 2.76; 95% confidence interval, 1.68 to 4.54). The avosentan-related CHF risk was higher with lower baseline cholesterol levels (P interaction=0.003) and concomitant statin use (P interaction=0.06), whereas it was lower with a lower estimated GFR (P interaction=0.04). Patients allocated to avosentan had a median body weight increase of 0.6 kg (interquartile range, 0.0 to 2.0 kg) and a median hemoglobin decrease of 1.4 g/dl (interquartile range, -2.1 to -0.7 g/dl) at the first postrandomization measurement. The body weight increase induced by avosentan was associated with CHF development (P interaction=0.04), whereas hemoglobin decrease was not (P interaction=0.64). The increase in body weight was particularly pronounced in patients with a cardiovascular disease history and in patients using statins. CONCLUSIONS: In avosentan-treated patients, body weight increase, but not hemoglobin decrease, was associated with CHF development, indicating that close body weight monitoring could provide an early signal of CHF development in future trials with endothelin receptor antagonists.
RCT Entities:
BACKGROUND AND OBJECTIVES: The Avosentan on Time to Doubling of Serum Creatinine, End Stage Renal Disease or Death (ASCEND) trial tested the renoprotective effect of the endothelin receptor antagonist avosentan in patients with diabetes and nephropathy, but the study was terminated due to an excess of congestive heart failure (CHF) events in the avosentan arms, likely due to fluid retention. The aim of this study was to identify risk markers of CHF after treatment with avosentan. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a post hoc analysis of the ASCEND trial (N=1392 participants), we assessed which baseline characteristics predicted CHF risk during avosentan treatment. Furthermore, postrandomization changes between baseline and the first available measurement of body weight and hemoglobin were examined as potential clinical indicators of fluid retention for their relationship with CHF development. RESULTS: Relative to placebo, avosentan increased CHF risk (hazard ratio, 2.76; 95% confidence interval, 1.68 to 4.54). The avosentan-related CHF risk was higher with lower baseline cholesterol levels (P interaction=0.003) and concomitant statin use (P interaction=0.06), whereas it was lower with a lower estimated GFR (P interaction=0.04). Patients allocated to avosentan had a median body weight increase of 0.6 kg (interquartile range, 0.0 to 2.0 kg) and a median hemoglobin decrease of 1.4 g/dl (interquartile range, -2.1 to -0.7 g/dl) at the first postrandomization measurement. The body weight increase induced by avosentan was associated with CHF development (P interaction=0.04), whereas hemoglobin decrease was not (P interaction=0.64). The increase in body weight was particularly pronounced in patients with a cardiovascular disease history and in patients using statins. CONCLUSIONS: In avosentan-treated patients, body weight increase, but not hemoglobin decrease, was associated with CHF development, indicating that close body weight monitoring could provide an early signal of CHF development in future trials with endothelin receptor antagonists.
Authors: W Philip T James; Ian D Caterson; Walmir Coutinho; Nick Finer; Luc F Van Gaal; Aldo P Maggioni; Christian Torp-Pedersen; Arya M Sharma; Gillian M Shepherd; Richard A Rode; Cheryl L Renz Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: Donald E Kohan; Yili Pritchett; Mark Molitch; Shihua Wen; Tushar Garimella; Paul Audhya; Dennis L Andress Journal: J Am Soc Nephrol Date: 2011-03-03 Impact factor: 10.121
Authors: Joel B Nelson; Karim Fizazi; Kurt Miller; Celestia Higano; Judd W Moul; Hideyuki Akaza; Thomas Morris; Stuart McIntosh; Kristine Pemberton; Martin Gleave Journal: Cancer Date: 2012-07-11 Impact factor: 6.860
Authors: Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer Journal: N Engl J Med Date: 2007-11-05 Impact factor: 91.245
Authors: J Smolander; B Vogt; M Maillard; C Zweiacker; T Littke; T Hengelage; M Burnier Journal: Clin Pharmacol Ther Date: 2009-03-11 Impact factor: 6.875
Authors: Inder Anand; John McMurray; Jay N Cohn; Marvin A Konstam; Thomas Notter; Kurt Quitzau; Frank Ruschitzka; Thomas F Lüscher Journal: Lancet Date: 2004 Jul 24-30 Impact factor: 79.321
Authors: Johannes F E Mann; Damian Green; Kenneth Jamerson; Luis M Ruilope; Susan J Kuranoff; Thomas Littke; Giancarlo Viberti Journal: J Am Soc Nephrol Date: 2010-02-18 Impact factor: 10.121
Authors: Simke W Waijer; Ron T Gansevoort; George L Bakris; Ricardo Correa-Rotter; Fan-Fan Hou; Donald E Kohan; Dalane W Kitzman; Hirofumi Makino; John J V McMurray; Vlado Perkovic; Sheldon Tobe; Hans-Henrik Parving; Dick de Zeeuw; Hiddo J L Heerspink Journal: Clin J Am Soc Nephrol Date: 2021-12-01 Impact factor: 8.237
Authors: Bauke Schievink; Dick de Zeeuw; Paul A Smink; Dennis Andress; John J Brennan; Blai Coll; Ricardo Correa-Rotter; Fan Fan Hou; Donald Kohan; Dalane W Kitzman; Hirofumi Makino; Hans-Henrik Parving; Vlado Perkovic; Giuseppe Remuzzi; Sheldon Tobe; Robert Toto; Jarno Hoekman; Hiddo J Lambers Heerspink Journal: Eur J Prev Cardiol Date: 2015-07-30 Impact factor: 7.804
Authors: Hiddo J L Heerspink; Dennis L Andress; George Bakris; John J Brennan; Ricardo Correa-Rotter; Jyotirmoy Dey; Fan Fan Hou; Dalane W Kitzman; Donald Kohan; Hirofumi Makino; John McMurray; Vlado Perkovic; Sheldon Tobe; Melissa Wigderson; Hans-Henrik Parving; Dick de Zeeuw Journal: Diabetes Obes Metab Date: 2018-03-09 Impact factor: 6.577